Exercise in the management of obesity

Metabolism, Journal Year: 2018, Volume and Issue: 92, P. 163 - 169

Published: Oct. 29, 2018

Language: Английский

---

2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea

Journal of Obesity & Metabolic Syndrome, Journal Year: 2021, Volume and Issue: 30(2), P. 81 - 92

Published: May 28, 2021

Obesity is a prevalent and complex disease. The prevalence of obesity in Korea increased from 29.7% 2010 to 35.7% 2018, with the abdominal being 23.8% 2018. contributes medical costs socioeconomic burden due associated comorbidities. treatment management changing based on new clinical evidence. 2020 Korean Society for Study Guideline Management summarizes evidence-based recommendations guidelines.

Language: Английский

---

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

New England Journal of Medicine, Journal Year: 2018, Volume and Issue: 379(12), P. 1107 - 1117

Published: Aug. 26, 2018

Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and of lorcaserin are undefined.We randomly assigned 12,000 patients with atherosclerotic disease multiple risk factors to receive either (10 mg twice daily) placebo. primary outcome major events (a composite death, myocardial infarction, stroke) was assessed at an interim analysis exclude noninferiority boundary 1.4. If met, the events, heart failure, hospitalization unstable angina, coronary revascularization [extended events]) superiority end trial.At 1 year, loss least 5% had occurred 1986 5135 (38.7%) group 883 5083 (17.4%) placebo (odds ratio, 3.01; 95% confidence interval [CI], 2.74 3.30; P<0.001). Patients slightly better values respect cardiac (including blood pressure, rate, glycemic control, lipids) than those group. During median follow-up 3.3 years, rate 2.0% per year 2.1% (hazard 0.99; CI, 0.85 1.14; P<0.001 noninferiority); extended 4.1% 4.2% respectively 0.97; 0.87 1.07; P=0.55). Adverse special interest were uncommon, rates generally similar two groups, except higher number serious hypoglycemia (13 vs. 4, P=0.04).In high-risk population patients, facilitated sustained without (Funded by Eisai; CAMELLIA-TIMI 61 ClinicalTrials.gov number, NCT02019264 .).

Language: Английский

---

The carbohydrate-insulin model: a physiological perspective on the obesity pandemic

American Journal of Clinical Nutrition, Journal Year: 2021, Volume and Issue: 114(6), P. 1873 - 1885

Published: July 27, 2021

According to a commonly held view, the obesity pandemic is caused by overconsumption of modern, highly palatable, energy-dense processed foods, exacerbated sedentary lifestyle. However, rates remain at historic highs, despite persistent focus on eating less and moving more, as guided energy balance model (EBM). This public health failure may arise from fundamental limitation EBM itself. Conceptualizing disorder restates principle physics without considering biological mechanisms that promote weight gain. An alternative paradigm, carbohydrate-insulin (CIM), proposes reversal causal direction. CIM, increasing fat deposition in body-resulting hormonal responses high-glycemic-load diet-drives positive balance. The CIM provides conceptual framework with testable hypotheses for how various modifiable factors influence storage. Rigorous research needed compare validity these 2 models, which have substantially different implications management, generate new models best encompass evidence.

Language: Английский

---

Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2019, Volume and Issue: 21(1), P. 5 - 16

Published: Nov. 9, 2019

Language: Английский

---

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design

American Heart Journal, Journal Year: 2020, Volume and Issue: 229, P. 61 - 69

Published: July 17, 2020

Cardiovascular disease (CVD) is a major cause of morbidity and mortality. Although it has been widely appreciated that obesity risk factor for CVD, treatments produce effective, durable weight loss the impact reduction in reducing cardiovascular have elusive. Instead, progress CVD achieved through medications indicated controlling lipids, hyperglycemia, blood pressure, heart failure, inflammation, and/or thrombosis. Obesity implicated as promoting all these issues, suggesting sustained, effective may independent benefit. GLP-1 receptor agonists (RAs) reduce weight, improve glycemia, decrease events those with diabetes, additional cardioprotective effects. The RA semaglutide phase 3 studies medication treatment at dose 2.4 mg subcutaneously (s.c.) once weekly. Semaglutide Effects on Heart Disease Stroke Patients Overweight or (SELECT) randomized, double-blind, parallel-group trial testing if weekly superior to placebo when added standard care preventing adverse patients established overweight but without diabetes. SELECT first outcomes evaluate superiority an antiobesity such population. As such, potential advancing new approaches while targeting obesity.

Language: Английский

---

Clinical management and treatment of obesity in China

The Lancet Diabetes & Endocrinology, Journal Year: 2021, Volume and Issue: 9(6), P. 393 - 405

Published: May 19, 2021

Language: Английский

---

Metabolic drivers of non-alcoholic fatty liver disease

Molecular Metabolism, Journal Year: 2020, Volume and Issue: 50, P. 101143 - 101143

Published: Dec. 18, 2020

The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide parallel to the global obesity epidemic. NAFLD encompasses a range pathologies and most often originates from metabolically driven accumulation fat in liver, or (NAFL). In subset NAFL patients, can progress steatohepatitis (NASH), which more severe form characterized by hepatocyte injury, inflammation, fibrosis. Significant has been made over past decade our understanding NASH pathogenesis, but gaps remain mechanistic knowledge precise metabolic triggers for worsening.

Language: Английский

---

Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association

Hypertension, Journal Year: 2021, Volume and Issue: 78(5)

Published: Sept. 20, 2021

Hypertension is a major risk factor for cardiovascular and renal diseases in the United States worldwide. Obesity accounts much of primary hypertension through several mechanisms, including neurohormonal activation, inflammation, kidney dysfunction. As prevalence obesity continues to increase, associated cardiorenal will also increase unless more effective strategies prevent treat are developed. Lifestyle modification, diet, reduced sedentariness, increased physical activity, usually recommended patients with obesity; however, long-term success these reducing adiposity, maintaining weight loss, blood pressure has been limited. Effective pharmacotherapeutic procedural strategies, metabolic surgeries, additional options or attenuate hypertension, target organ damage, subsequent disease. Medications can be useful short- treatment; prescription drugs Metabolic surgery producing sustained loss treating disorders many severe obesity. Unanswered questions remain related mechanisms obesity-related diseases, efficacy different treatment prevention timing interventions hypertension-mediated damage. Further investigation, randomized controlled trials, essential addressing questions, emphasis should placed on reduce burden hypertensive mortality.

Language: Английский

---

Advances and prospects in the food applications of pectin hydrogels

Critical Reviews in Food Science and Nutrition, Journal Year: 2021, Volume and Issue: 62(16), P. 4393 - 4417

Published: Jan. 29, 2021

Pectin hydrogel is a soft hydrocolloid with multifaceted utilities in the food sector. Substantial knowledge acquired on gelation mechanisms and structure-function relationship of pectin has led to interesting functions hydrogel. Food applications hydrogels can be categorized under four headings: ingredients/additives, packaging, bioactive delivery health management. The cross-linked tangly three-dimensional structure gel renders it an ideal choice wall material for encapsulation biomolecules living cells; as fat replacer texturizer. Likewise, effective satiety inducer due its ability swell simulated gastric intestinal conditions without losing structure. Coating or composites proteins other polysaccharides augment functionality encapsulant, satiety-inducer packaging material. Low-methoxyl appropriate ink 3D printing viscoelastic properties, adaptable microstructure texture properties. This review aims at explaining all hydrogels, mentioned above. A comprehensive discussion presented approaches by which transformed resourceful controlling dimensions, state, rheology. final sections this article emphasize recent research trends discipline, such development smart injectable gels, aerogels, xerogels oleogels from pectin.

Language: Английский

---